OTCMKTS:ECTE - Echo Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Echo Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.0049 0.00 (0.00 %) (As of 01/26/2020 04:00 PM ET) Add Compare Today's Range$0.00Now: $0.00▼$0.0050-Day Range$0.00MA: $0.01▼$0.0152-Week Range$0.00Now: $0.00▼$0.04Volume10,662 shsAverage Volume12,828 shsMarket Capitalization$65,170.00P/E RatioN/ADividend YieldN/ABeta9.71 ProfileAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Echo Therapeutics, Inc engages in the development of transdermal skin permeation and diagnostic medical devices for wearable-health consumer and diabetes outpatient markets. It is developing continuous glucose monitoring (CGM) system, a needle-free wireless continuous glucose monitoring system in a hospital setting in the European Union. The company has a licensing agreement with Ferndale Pharma Group, Inc to develop, manufacture, distribute, and market devices for skin preparation prior to the application of topical anesthetics or analgesics prior to a range of needle-based medical procedures in North America, the United Kingdom, South America, Australia, New Zealand, Switzerland, and other portions of the European Community. Read More… Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Electromedical equipment Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:ECTE Previous SymbolNASDAQ:ECTE CUSIPN/A CIK1031927 Webhttp://www.echotx.com/ Phone732-549-0128Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees19 Outstanding Shares13,300,000Market Cap$65,170.00 Next Earnings DateN/A OptionableNot Optionable Receive ECTE News and Ratings via Email Sign-up to receive the latest news and ratings for ECTE and its competitors with MarketBeat's FREE daily newsletter. OTC:ECTE Rates by TradingView Echo Therapeutics (OTCMKTS:ECTE) Frequently Asked Questions What is Echo Therapeutics' stock symbol? Echo Therapeutics trades on the OTCMKTS under the ticker symbol "ECTE." How were Echo Therapeutics' earnings last quarter? Echo Therapeutics Inc (OTCMKTS:ECTE) announced its quarterly earnings data on Friday, August, 12th. The medical device company reported ($0.82) earnings per share for the quarter. During the same quarter last year, the company earned ($0.97) EPS. View Echo Therapeutics' Earnings History. Has Echo Therapeutics been receiving favorable news coverage? Media stories about ECTE stock have trended extremely negative on Sunday, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Echo Therapeutics earned a news sentiment score of -4.5 on InfoTrie's scale. They also gave news headlines about the medical device company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the next several days. View News Stories for Echo Therapeutics. Who are some of Echo Therapeutics' key competitors? Some companies that are related to Echo Therapeutics include Magna-Lab (MAGAA), Newcardio (NWCI), 21st North (ULGX), IMRIS (IMRSQ) and SpectraScience (SCIE). What other stocks do shareholders of Echo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Echo Therapeutics investors own include DexCom (DXCM), NovaBay Pharmaceuticals (NBY), Acer Therapeutics (ACER), Biocept (BIOC), Rexahn Pharmaceuticals (REXN), CytRx (CYTR), InterCloud Systems (ICLD), SLS International (SLS), Athersys (ATHX) and Aware (AWRE). Who are Echo Therapeutics' key executives? Echo Therapeutics' management team includes the folowing people: Mr. Alan W. Schoenbart CPA, Chief Exec. Officer, Chief Financial Officer and Director (Age 60) How do I buy shares of Echo Therapeutics? Shares of ECTE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Echo Therapeutics' stock price today? One share of ECTE stock can currently be purchased for approximately $0.00. How big of a company is Echo Therapeutics? Echo Therapeutics has a market capitalization of $65,170.00. Echo Therapeutics employs 19 workers across the globe.View Additional Information About Echo Therapeutics. What is Echo Therapeutics' official website? The official website for Echo Therapeutics is http://www.echotx.com/. How can I contact Echo Therapeutics? Echo Therapeutics' mailing address is 99 WOOD AVENUE SOUTH SUITE 302, ISELIN NJ, 08830. The medical device company can be reached via phone at 732-549-0128 or via email at [email protected] MarketBeat Community Rating for Echo Therapeutics (OTCMKTS ECTE)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 164 (Vote Outperform)Underperform Votes: 139 (Vote Underperform)Total Votes: 303MarketBeat's community ratings are surveys of what our community members think about Echo Therapeutics and other stocks. Vote "Outperform" if you believe ECTE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ECTE will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/26/2020 by MarketBeat.com StaffFeatured Article: How does the Beige Book influence monetary policy?
